Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals SPPI
report update icon

Quarterly report 2023-Q1
added 11-21-2026

Spectrum Pharmaceuticals Revenue | SPPI

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Spectrum Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
10.1 M - - - 109 M 128 M 146 M 137 M 187 M 143 M 255 M 181 M - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
255 M 10.1 M 144 M

Quarterly Revenue Spectrum Pharmaceuticals

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
15.6 M - - - - - - - - - - - - - - - - 29.4 M 25.3 M 24.2 M 30.5 M 28.6 M 36.4 M 34.3 M 29.1 M 50 M 30.3 M 30.9 M 35.2 M 34.8 M 28.5 M 35.1 M 38.4 M 51.7 M 47.9 M 46.9 M 40.1 M 40.5 M 41.4 M 32.2 M 29.3 M 70.1 M 69 M 68.7 M 59.9 M 53 M 51 M 45.4 M 43.6 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
70.1 M 15.6 M 40.2 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
172 M $ 8.71 -4.16 % $ 755 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
44.5 M $ 3.47 -6.48 % $ 371 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
1.58 M $ 0.59 -4.42 % $ 36.2 M usaUSA
Jaguar Health Jaguar Health
JAGX
11.5 M $ 0.24 -27.06 % $ 560 K usaUSA
Arvinas Arvinas
ARVN
263 M $ 6.41 -4.9 % $ 454 M usaUSA
Cerus Corporation Cerus Corporation
CERS
234 M $ 1.86 -2.37 % $ 355 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
140 M $ 20.87 -0.36 % $ 2.06 B usaUSA
Inhibrx Inhibrx
INBX
1.8 M $ 68.81 -7.43 % $ 3.24 B usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
33.2 M $ 48.09 -4.54 % $ 5.52 B usaUSA
Revolution Medicines Revolution Medicines
RVMD
11.6 M $ 161.01 0.99 % $ 30.6 B usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
42 K $ 3.29 0.15 % $ 152 M israelIsrael
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
85.6 M - - $ 459 M usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
627 M $ 15.21 -5.53 % $ 5.61 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
76.2 M $ 2.04 -0.73 % $ 281 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
1.14 M $ 2.67 2.9 % $ 1.81 M chinaChina
Krystal Biotech Krystal Biotech
KRYS
389 M $ 308.83 -2.21 % $ 8.94 B usaUSA
Kura Oncology Kura Oncology
KURA
67.5 M $ 6.91 -6.05 % $ 606 M usaUSA
Inhibikase Therapeutics Inhibikase Therapeutics
IKT
261 K $ 1.31 0.38 % $ 129 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
2.95 M $ 2.28 -5.21 % $ 97.7 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
155 M $ 0.25 -5.3 % $ 41.7 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
65.3 K $ 1.76 2.63 % $ 82.5 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
57.6 M $ 2.66 -0.37 % $ 32.8 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
2.95 M - -5.76 % $ 99.8 M usaUSA
Innoviva Innoviva
INVA
411 M $ 18.42 0.03 % $ 1.24 B usaUSA
BioCardia BioCardia
BCDA
58 K $ 0.77 -0.08 % $ 5.13 M usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
1.22 B $ 72.69 -0.01 % $ 11.3 B usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
42.2 M - 0.11 % $ 419 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
109 K $ 1.52 -8.16 % $ 9.72 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
23.7 M - -3.90 % $ 97.2 M chinaChina
Certara Certara
CERT
419 M $ 10.56 -1.12 % $ 1.69 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
113 M $ 13.26 -0.15 % $ 190 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
5 K $ 1.59 -5.92 % $ 2.08 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
761 M $ 63.61 -2.11 % $ 6.61 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
74.3 M - -3.47 % $ 164 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
30.7 M - 1.52 % $ 136 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
55.2 M $ 30.23 -7.1 % $ 510 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
9 M $ 0.87 -7.57 % $ 77.9 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
13.5 K - -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
3.22 B $ 60.42 -1.64 % $ 11.6 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
1.1 M $ 0.75 -9.23 % $ 4.11 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
63 M $ 7.6 -4.82 % $ 220 M usaUSA
Lipocine Lipocine
LPCN
1.98 M $ 1.47 -2.33 % $ 8.01 M usaUSA